Results 161 to 170 of about 75,066 (195)

Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study. [PDF]

ACR Open Rheumatol
Frier K, Dietl M, Aronson S, Dhani J, James K, Betensky D, Selzer F, Losina E, Katz JN, Kim JS, Weiss-Laxer NS.   +10 more
europepmc   +1 more source

Impact of bariatric surgery on alcohol‐use disorder and alcohol‐related liver disease: A retrospective study

Addiction, EarlyView.
Abstract Background and aims Increased risk of alcohol dependence is recognised following bariatric surgery. Modified gastrointestinal anatomy and neurohormonal profiles lead to altered alcohol metabolism, peak blood alcohol concentrations and enhanced reward circuits and cravings.
Thomas J. Williams, Andrew J. Palmer, Jason P. Connor, Gerald Holtmann, Paul J. Clark   +4 more
wiley   +1 more source

Effects of the glucagon-like peptide-1 receptor agonist PEG-Loxe on diabetic osteoporosis: A mechanistic study. [PDF]

Mol Metab
Zhang L, Hu J, Huang C, Gao X, Pang D, Duan L.   +5 more
europepmc   +1 more source

Evidence of a Protective Effect of Metformin on Abdominal Aortic Aneurysm Risk: Insights From an Observational Study and Mendelian Randomisation Analysis Using Putative Metformin Targets

Annals of Human Genetics, EarlyView.
ABSTRACT Aims There is no proven treatment to prevent the growth or rupture of abdominal aortic aneurysm (AAA). As an aneurysm enlarges over time, the risk of fatal aortic rupture increases. Metformin, a drug usually prescribed to treat Type 2 diabetes, has previously been associated with reduced AAA risk in observational studies. Our aim was to assess
Katie Louise Saxby, Svetlana Stoma, Frank Dudbridge, Nilesh J. Samani, Matthew J. Bown, Christopher P. Nelson   +5 more
wiley   +1 more source

Distribution of glucagon-like peptide 1 receptor and insulin in phaeochromocytomas. [PDF]

Endocr Connect
Følling I, Selle ML, Nilsen HR, Wennerström AB, Nilsen HL, Eide TJ.   +5 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Prescriptions for Glucagon-Like Peptide 1 Agonists (GLP-1RAs) Before Bariatric Surgery in the US. [PDF]

Ann Surg
Zion A, Segal JB, Mehta HB.
europepmc   +1 more source

Identification of MEF2A, MEF2C, and MEF2D interactomes in basal and Fsk‐stimulated mouse MA‐10 Leydig cells

Andrology, EarlyView.
Abstract Background Myocyte enhancer factor 2 transcription factors regulate essential transcriptional programs in various cell types. The activity of myocyte enhancer factor 2 factors is modulated through interactions with cofactors, chromatin remodelers, and other regulatory proteins, which are dependent on cell context and physiological state.
Karine de Mattos, Marie‐Pier Scott‐Boyer, Arnaud Droit, Robert S. Viger, Jacques J. Tremblay   +4 more
wiley   +1 more source

Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.

J Clin Endocrinol Metab
Fabbrini E, Koshkina A, Hackett M, Zhao M, Thalluri K, Hompesch M, Macias A, Schneider K, D'Alessio DA, DiMarchi RD, Azoulay S.   +10 more
europepmc   +1 more source

Cancer Incidence Among Users of Glucagon-Like Peptide-1 Receptor Agonists. [PDF]

J Gen Intern Med
Rashid Z, Woldesenbet S, Khalil M, Altaf A, Zindani S, Mevawalla A, Sarfraz A, Mumtaz K, Pawlik TM.   +8 more
europepmc   +1 more source